Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
REGULATORY Another Daiichi Sankyo Veteran to Take Over as Provost of SCARDA
March 15, 2024
-
REGULATORY Japan Begins Discussions on RSV Vaccines for National Immunization Program
March 15, 2024
-
REGULATORY Japan to Set Value-Based Share of 65% as Secondary Target for Generic Use
March 15, 2024
-
BUSINESS Takeda Settles on Lower Pay Hike than 2023; Union Group Says Pharma Labor Talks Tougher than Others
March 15, 2024
-
BUSINESS Meiji/KM Biologics’ 5-in-1 Vaccine Now Available Ahead of NIP Rollout
March 15, 2024
-
BUSINESS Ono, Sibylla Strike Neuroscience Drug Discovery Pact
March 15, 2024
-
BUSINESS Daiichi Sankyo’s TROP2 ADC Now under Review for Breast Cancer in Japan
March 15, 2024
-
BUSINESS Chugai Submits Mosunetuzumab for Follicular Lymphoma in Japan
March 15, 2024
-
BUSINESS Tecentriq Filed for Alveolar Soft Part Sarcoma in Japan: Chugai
March 15, 2024
-
REGULATORY Xocova Set for Renewed Price-Setting after Full Approval, Big Cut Unlikely
March 14, 2024
-
REGULATORY PD-1/PD-L1, JAK Drugs to Be Exempt from Spillover Price Cuts: Chuikyo
March 14, 2024
-
REGULATORY CellCept, Paraplatin Now Eligible for Health Coverage
March 14, 2024
-
REGULATORY LEO Pharma’s Eczema Drug Adtralza OK’ed for Self-Injection
March 14, 2024
-
BUSINESS High Demand Triggers Shipment Curb for G-Lasta Biosimilars
March 14, 2024
-
REGULATORY Lagevrio, Kerendia Braced for Price Cuts after Cost-Effectiveness Assessment
March 14, 2024
-
BUSINESS Takeda Taps Asuka Miyabashira as New Japan Pharma Chief
March 14, 2024
-
REGULATORY Disclosure Guidelines on Generic Supply Info Up for Public Comments
March 13, 2024
-
BUSINESS Novo Gears Up Sustainability Efforts by Recycling Injectors in Japan
March 13, 2024
-
REGULATORY Japan Needs Systemic Reform to Balance Universal Coverage and Access to Pricey Meds: LDP Health Affairs Chief
March 13, 2024
-
BUSINESS Full Resumption of Quake-Hit Santen Plant Delayed into April
March 13, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…